Promising experimental MS drug trial testing in Seattle
KING5.com (subscription) - Seattle,WA,USA
OHSU professor of neurology Arthur Vandenbark developed the drug RTL1000. In earlier stages of research, his team took mice paralyzed by MS and gave them ...
See all stories on this topic

Blindness treatment looks positive
Sarasota Herald-Tribune - Sarasota,FL,USA
The company in China has performed 6000 stem cell treatments for multiple sclerosis, ataxia, stroke, spinal cord injury, traumatic brain injury and other ...
See all stories on this topic

Research and Markets: New Report Predicts that Novartis' Diovan ...
PharmaLive.com (press release) - Newtown,PA,USA
Of particular note are: Galvus (vildagliptin), filed for Type II diabetes in the US and the EU; and fingolimod under Phase III development for multiple ...
See all stories on this topic

FDA Hesitates To Approve Biogen, Elan's Tysabri As Treatment For ...
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
Jul 30, 2007 (financialwire.net via COMTEX) -- July 30, 2007 (FinancialWire) The Food and Drug Administration has said that it was hesitant to allow Tysabri ...
See all stories on this topic

FDA panel backs Tysabri for Crohn's
Boston Globe - United States
The Food and Drug Administration advisory panel meeting yesterday on Tysabri. (Stephanie Kuykendal/Bloomberg News) By Jeffrey Krasner, Globe Staff | August ...
See all stories on this topic

Early Interferon Therapy in MS Reduces Progression Risk
MedPage Today - Little Falls,NJ,USA
The primary results of that study showed that intervention with interferon beta-1b at the first clinical event suggestive of multiple sclerosis ...
See all stories on this topic

Multiple sclerosis: Early treatment slows progression
AFP via Yahoo! News Thu, 02 Aug 2007 6:26 PM PDT
Early use of the drug interferon beta-1b can significantly delay progression of multiple sclerosis (MS), according to a study published in this Saturday's Lancet.

Risk Genes For Multiple Sclerosis Revealed By Research Teams
Medical News Today Fri, 03 Aug 2007 8:11 AM PDT
Two new large-scale genomic studies have honed in on the main genetic pathway associated with multiple sclerosis (MS), while also uncovering new genetic variations in the disease and suggesting a possible link between MS and other autoimmune diseases. [click link for full article]

Early interferon therapy may delay MS disability
Reuters via Yahoo! News Fri, 03 Aug 2007 9:37 AM PDT
Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue of the UK medical journal, The Lancet.

Early Interferon Treatment Delays MS
HealthDay via Yahoo! News Thu, 02 Aug 2007 4:01 PM PDT
THURSDAY, Aug. 2 (HealthDay News) -- Early treatment with the drug interferon slows the progression of multiple sclerosis (MS) in people with the first symptoms of the disease and reduces impairment, a Swiss study shows.